Clinical Trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07846683) titled 'A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis' on Sept. 10.

Brief Summary: The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulcerative colitis (UC).

Study Start Date: Nov. 15

Study Type: INTERVENTIONAL

Condition: Moderately to Severely Active Ulcerative Colitis

Intervention: DRUG: Afimkibart

Afimkibart will be administered as SC injection.

DRUG: Placebo

Placebo will be administered as SC injection.

Recruitment Status...